<DOC>
	<DOCNO>NCT01333085</DOCNO>
	<brief_summary>RATIONALE : Everolimus may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , carboplatin paclitaxel , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase I/II trial study side effect best dose give everolimus together carboplatin paclitaxel treat patient locally advanced head neck cancer remove surgery .</brief_summary>
	<brief_title>Everolimus , Carboplatin , Paclitaxel Locally Advanced Head Neck Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum-tolerated dose everolimus combine carboplatin paclitaxel chemonaïve patient unresectable inoperable locally advanced head neck squamous cell carcinoma . ( Phase I ) - To determine safety profile weekly everolimus combination carboplatin paclitaxel chemonaïve patient unresectable inoperable locally advanced head neck squamous cell carcinoma . ( Phase I ) - To determine anti-tumor activity regimen , term objective response rate combination , accord RECIST criterion patient . ( Phase II ) Secondary - To identify molecular marker resistance regimen patient . - To assess objective response rate completion radiation therapy patient . ( Phase II ) OUTLINE : This multicenter , phase I dose-escalation study everolimus follow phase II study . - Phase I : Patients receive paclitaxel IV 1 hour , carboplatin IV 1 hour , escalate dos oral everolimus day 1 , 8 , 15 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . - Phase II : Patients receive paclitaxel carboplatin phase I oral everolimus ( dose determine phase I portion study ) day 1 , 8 , 15 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . After completion combination therapy , patient may receive radiotherapy surgery , investigator 's discretion . Blood sample collect translational research molecular marker analysis baseline week 1 , 4 , 9 . Tissue sample collect baseline periodically study biomarker laboratory analysis . After completion study treatment , patient follow 14 day periodically thereafter .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma oral cavity , oropharynx , larynx , hypopharynx Locally advanced disease ( T4 N0N3 disease ) Unresectable disease OR resectable disease surgery contraindication No stage I , II , III , IVc disease Measurable lesion define accurately measure ≥ 1 dimension ( long diameter record ) ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan No known brain metastasis ( cerebral CT scan require symptom present ) PATIENT CHARACTERISTICS : WHO performance status 02 Life expectancy &gt; 3 month Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9 g/dL Total bilirubin ≤ 1.25 time upper limit normal ( ULN ) Transaminases ≤ 2.5 time ULN Alkaline phosphatase ≤ 5 time ULN Creatinine clearance ≥ 60 mL/min Glycemia ≤ 1.5 time ULN Cholesterol level ≤ 7.30 mmol/L Serum total protein normal Oxygen saturation &gt; 88 % Able swallow pill Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment No preexisting neuropathy ≥ grade 2 No uncontrolled disease include follow : Diabetes Hypertension Symptomatic congestive heart pulmonary failure Renal hepatic chronic disease Severe infectious disease No active hemorrhagic syndrome No prior history cancer within past 5 year , except situ cervical cancer basal cell skin carcinoma No psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule Registration national health care system ( CMU include ) Not eligible organ preservation program PRIOR CONCURRENT THERAPY : No prior therapy cancer No prior chemotherapy unless receive treatment another primary tumor consider remission No prior investigational drug More 30 day since prior participation another therapeutic trial No prior concurrent radiotherapy ( except anterior radiotherapy ) unless receive treatment another primary tumor consider remission No concurrent CYP3A4 strong inhibitor ( e.g. , azole antimycotic [ itraconazole , ketoconazole ] , HIV protease inhibitor [ ritonavir ] , erythromycin , antiepileptic drug [ phenytoin , carbamazepine ] ) No concurrent anticoagulant therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV verrucous carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>tongue cancer</keyword>
</DOC>